additional data on the HCAI-DCS website. Centres were also contacted by phone and email as a further validation step. Results: From April 2009-2010 there were 77 confirmed episodes of MRSA bacteraemia at a median rate of 0.25 per 100 prevalent dialysis patients. This number decreased to 61 episodes between April 2010-2011 at a median rate of 0 per 100 prevalent dialysis patients. Overall there has been an 82% reduction in absolute episodes since the first year of mandatory reporting in 2007. The incidence of bacteraemia in patients with a central venous catheter was approximately six fold higher than in those with an AV fistula. From 1st January to 30th June 2011 there were 160 episodes of MSSA bacteraemia with a rate of 1.06 episodes per 100 dialysis patients, again the risk was six fold higher in patients with a CVC. Conclusions: Overall rates of MRSA bacteraemia in dialysis patients continued to fall although there remained variation between renal centres. Initial data from the early days of MSSA reporting suggested high rates of infection and an even greater variation between renal centres. This requires confirmation from future data collection.
Introduction
Infection remains the second leading cause of death in patients with established renal failure (ERF) receiving renal replacement therapy (RRT) [1, 2, 3] . High rates of systemic infection amongst haemodialysis patients are related to a decreased level of immunity, a high frequency of invasive treatment and the type of vascular access in use. Venous catheters have a higher reported rate of bacteraemia in comparison to arteriovenous fistulas (AVF) [4, 5] .
In the 2009 Renal Registry Report, the UK Renal Registry and the Health Protection Agency reported the epidemiology of Methicillin Resistant Staphylococcus Aureus (MRSA) bacteraemia in dialysis patients based on data collected between 1st April 2008 and 31st March 2009. These data were supplied by clinical staff and captured using a secure web-based system, the Healthcare Associated Infection Data Collection System (HCAI-DCS). A final round of data validation was also undertaken which involved emailing the clinical or infection control leads at each renal centre in order for them to check the details and accept the record. The dataset included dialysis modality, type of dialysis access and use of non-tunnelled venous catheters within the preceding 28 days. The analysis confirmed that dialysis patients continue to be at increased risk of MRSA bacteraemia with a total of 153 episodes in this period. However continuing a trend of reduced bacteraemia rates reported in 2007 [6] , there had been a decline of 22% from the previous year. The presence of a central venous catheter was associated with an almost seven fold higher risk of developing a bacteraemia. There remained considerable variation between renal centres in term of infection rates [7] .
This report contains analysis relating to the third and fourth years of this surveillance system. In 2011 mandatory surveillance of Methicillin Sensitive Staphylococcus Aureus (MSSA) bacteraemia was also introduced and this report describes the first 6 months of this surveillance, from 1st January 2011 to 30th June 2011.
Methods
MRSA bacteraemia data are presented from between the 1st April 2009 and the 31st March 2011. MSSA bacteraemia data are presented from 1st January 2011 to the 30th June 2011. The methods used have been described in previous registry reports [6, 7] . Briefly, four stages of data collection and validation were undertaken:
1 Identification of Staphylococcal bacteraemias potentially associated with dialysis patients. Records of patients reported by the laboratory to have staphylococcal bacteraemia were reviewed locally to identify those in ERF. 2 This record was then 'shared' with the parent renal centre. This required the laboratory staff to select the renal centre responsible for the dialysis of the patient which in turn triggered an email alert to be sent to the identified contact within the parent renal centre. 3 The renal centre then completed the additional renal data on the case via the HCAI-DCS website. 4 An additional validation and data capture step has been introduced to follow up records that were not shared or completed. This involved emailing clinical or infection control leads with details of the cases. This allowed case completion, and the parent renal centre to accept that episodes were related to patients in ERF requiring dialysis or reject them if the patient was not in ERF. Each individual renal centre was asked to complete and accept the record.
This data reporting mechanism applies only to renal centres in England and is not utilised in Wales, Scotland or Northern Ireland.
Results

Organisational results: 2009-2010
Between 1st April 2009 and 31st March 2010 a total of 87 records submitted to the Health Protection Agency via the HCAI-DCS were identified as being possibly associated with ERF requiring dialysis (table 12.1). Table 12 .1 details the numbers of records shared and completed by each renal centre via HCAI-DCS. Of these, 72 records were shared with the identified contact within the renal centre by laboratory staff, clinical details for the remainder were identified by direct contact with the clinical director of the renal centre concerned. Of the shared records 10 were completed via the web portal system giving a completion rate of 14% (10/72). For the remaining records clinical details were obtained again by direct contact with the clinical lead for the individual renal centre.
In total there were 77 accepted episodes of MRSA bacteraemia in patients in ERF during this time period. Of the remaining ten episodes, two were duplicate records, three were excluded as they were paediatric patients, one was a transplant patient and four were excluded as they were not patients with end-stage renal failure; these patients were rejected by their centres at the final stage of validation. Five centres were unable to provide validation within the necessary time frame (London Royal Free, Brighton, Portsmouth, Dudley, Shrewsbury). In these instances all episodes of MRSA bacteraemia attributed to these centres were included. Figure 12 .1 and table 12.2 provide breakdowns by modality and access. There were two patients reported to be on peritoneal dialysis at the time of the MRSA episode although one of these patients had a temporary venous catheter in-situ. The remainder were all haemodialysis patients. There were 15 patients where modality and access type were not recorded either because they were not available or because the data was not validated by the renal centre in time.
Access and modality data
In total 37 patients had a tunnelled venous catheter in-situ at the time of bacteraemia while 19 were dialysing via an arteriovenous fistula, four via an arteriovenous graft, two were end-stage renal failure patients dialysing via a temporary venous catheter and one patient had a peritoneal dialysis catheter in-situ (table 12. 2).
If it is assumed a 25% usage of venous catheters for the prevalent dialysis population [2, 3] the relative risk of MRSA bacteraemia can be estimated to be approximately six fold higher in patients with a venous catheter compared with those dialysing via an AVF.
Individual episodes
In total 68 patients had an MRSA bacteraemia. Fiftynine had a single episode whilst nine patients had two (table 12. 3).
Centre level data
The absolute number of MRSA episodes per centre are detailed in figure 12.1. The median absolute number of episodes per centre was one (range 0 to 9). Seventeen centres recorded no episodes of MRSA bacteraemia. The highest number of episodes in an individual centre was nine at St. Helier (Carshalton). order to adjust for variation in precision of estimated rate, the rate of bacteraemia per 100 prevalent haemodialysis patients for each centre has been plotted against the centre size in a funnel plot (figure 12.3). No centre had a rate in excess of 2 per 100 prevalent haemodialysis patients per year and no centre exceeded the upper 99% confidence line in the funnel plot (figure 12.3). 
Access and modality data
All patients whose data were validated were receiving haemodialysis for ERF. There were 30 patients where it was not possible to verify the mode of access (table  12. 2). Of the remaining 31, 22 dialysed via a tunnelled venous catheter, 11 via an arteriovenous fistula, one via an arteriovenous graft and one via a non-tunnelled catheter. Overall, the rate of bacteraemia was 5.75 times higher in patients with a venous catheter compared to those with an AVF (table 12. 2). prevalent dialysis patients as the denominator, the median rate was 0.0 with a range of 0 to 1.79 per 100 prevalent dialysis patients per year. Only Arrowe Park hospital (Wirral) had a rate greater than 2 per 100 prevalent haemodialysis patients. No renal centre exceeded the 99% upper confidence limit from the funnel plot (figure 12.6) and only Sheffield plotted above the 95% upper confidence limit, but it would be expected by chance that three centres would fall outside the 95% limits. 
Centre level data
Methicillin Sensitive Staphylococcus Aureus
The time period between 1st January 2011 and 30th June 2011 represented the first six months of mandatory reporting of Methicillin Sensitive Staphylococcus Aureus (MSSA) bacteraemia. Data were collected using the same process of sharing and validation described above. These data are likely to be an incomplete data set given the transition to mandatory MSSA reporting is still ongoing.
In total 170 episodes of MSSA bacteraemia were identified as being associated with patients in ERF (table 12.6). Ninety were shared and a further 80 were allocated by direct contact with the clinical lead for the each renal centre. Twenty-four were completed via the web portal system giving a completion rate of 27% (24/90) among shared records. Following validation from the individual renal centres, a further nine episodes were excluded giving a total number of 161 MSSA bacteraemia episodes in this six month period. Of the excluded patients, four were not in ERF, three were not known to the renal centre they were allocated to, one was excluded as a paediatric patient and one excluded as the centre they were allocated to was not a renal centre.
Access and modality data
It was possible to obtain access data on 92 of these episodes (table 12.7). In total there were 60 episodes where the patient was dialysing through a tunnelled venous catheter, 28 where the patient was dialysing via an arteriovenous fistula, two episodes involving an AV graft and two associated with a temporary line. In the remaining patients it was not possible to verify their mode of access within the timeframe of this report. Episodes by renal centre, coded for access are demonstrated in figure 12.8.
The risk of an MSSA bacteraemia was 6.1 fold higher in patients dialysing via a venous catheter.
Centre level data
The normalised centre specific rates based on the dialysis population at the end of 2010 demonstrate considerable variation (figure 12.9). Overall the median number of episodes per 100 prevalent haemodialysis patients was 1.27 with a rate of 1.06 per 100 prevalent dialysis patients per year. The range across centres was Total0.0 to 7.7. Ten centres did not report any episodes of MSSA bacteraemia, although this may be because dialysis details for MSSA episodes were not being reported to the mandatory system by that laboratory. Sixteen centres reported an incidence in excess of 2 per 100 prevalent dialysis patients.
Discussion
Infection remained a leading cause of death in dialysis patients and was exceeded only by cardiovascular disease. Type of access can itself be a major factor either by acting as a portal of entry and becoming the primary source of a bacteraemia or by the catheter becoming colonised as a result of another infective episode (i.e. skin and soft tissue, pneumonia). Dialysis patients continue to be at increased risk of MRSA bacteraemia. This is the third and fourth years of the full working of reporting via the Health Protection Agency of MRSA bacteraemias, also presented here are the first six months of reporting of MSSA.
As shown in figure 12.7, the reported figures represent a significant decline in MRSA rates in patients with ERF on dialysis compared with previous years. The decline has continued year on year with an overall reduction of The data on MSSA bacteraemia represent the first efforts at surveillance and therefore there is no comparable data available to give an idea of rates. In addition, only the first six months of 2011 are given but if the data are extrapolated this would indicate 320 cases of MSSA per year. There is a noticeably higher incidence of MSSA infection when compared with recently reported MRSA rates suggesting that MSSA bacteraemia continues to be a significant problem amongst ERF patients.
The reasons for the discrepancy are not analysed in this report. Whilst one would expect a higher rate of MSSA it For each centre the rate per 100 prevalent HD patients as reported 31/12/2010 is provided The overall rate for England is provided at the top of the graph would be reasonable to extrapolate from the first six months of the year that there were nearly 320 MSSA infections among dialysis patients in 2011. As this is the first year of the surveillance system there may be an element of reporting bias. Staphylococcus aureus is recognised as a major cause of vascular device-associated infection and the success of MRSA screening and eradication programmes may have favoured the elimination of MRSA strains but left patients still vulnerable to infection by MSSA. It is also noticeable that some centres with little or no MRSA may have a high incidence of MSSA bacteraemia. Further work is needed to demonstrate the overall trend of MSSA bacteraemia amongst dialysis patients.
Conclusion
The third and fourth years of mandatory reporting of MRSA have continued to show a decline in infection rates in renal centres in England with an overall drop of over 80% since 2008. The first six months of mandatory MSSA reporting show a higher rate of infection and more data are required to understand the risks and trends amongst ERF patients.
Infection remains a considerable cause of morbidity and mortality amongst ERF patients and the presence of a tunnelled venous catheter continues to be a considerable risk factor for developing bacteraemia.
